GPC Biotech

Contact
gpc-biotech.com
+498985652600

GPC Biotech AG

Fraunhoferstraße 20
82152 Martinsried
Germany
+498985652600
gpc-biotech.com
Contact
Profile Products News
Contact

About GPC Biotech

GPC Biotech's mission was to discover and develop novel anti-cancer drugs. The founding team raised two private financing rounds in 1997 and 1999, acquired a Boston-based drug discovery company, took GPC public in 2000 and listed GPC on Nasdaq in 2004. It developed an anti-cancer drug through clinical phase 3 and filed for market registration. In 2009, GPC Biotech merged with the US-based company Agennix Inc.

Read more about GPC Biotech
Facts about GPC Biotech
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of GPC Biotech

Product portfolio

Show all

News about GPC Biotech

GPC Biotech

12-Oct-2009 | business & finance

GPC Biotech Merger into new Agennix AG on track to close before the end of 2009

GPC Biotech AG reported that its planned merger, under which the Company will combine its business with Agennix Incorporated remains on track to close ...

Read news
GPC Biotech

24-Jun-2009 | business & finance

GPC Biotech Shareholders Approve Merger into New Agennix AG

GPC Biotech AG announced that the shareholders' meeting approved the adoption of the merger agreement between the Company and diagennix GmbH (to be renamed ...

Read news
GPC Biotech

20-Feb-2009 | business & finance

GPC Biotech and Agennix Announce Proposed Merger

Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing

Read news
GPC Biotech

29-Jul-2008 | research and development

GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn

GPC Biotech AG reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorization ...

Read news
GPC Biotech

17-Jun-2008 | research and development

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

GPC Biotech AG announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, an oral platinum compound. The patent is entitled, " ...

Read news
GPC Biotech

05-Dec-2007 | people

GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer

GPC Biotech AG announced the appointment of Torsten Hombeck, Ph.D., to Chief Financial Officer. Dr. Hombeck will assume his duties on January 1, 2008. Dr. ...

Read news
GPC Biotech

01-Aug-2007 | research and development

GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval

Company Plans to Resubmit Application Pending Final Survival Analysis

Read news
GPC Biotech

31-Jul-2007 | business & finance

GPC Biotech AG Named in Purported Class Action Lawsuit in the United States

GPC Biotech AG announced that it has been sued in the United States District Court for the Southern District of New York, purportedly in a class action ...

Read news
Show more news about GPC Biotech

Here you will find GPC Biotech AG